Form 4: Astera Labs President and COO Sells Over 165,000 Shares Under Pre-Arranged Trading Plan

Astera Labs' President and COO, Sanjay Gajendra, sold 165,000 shares of common stock on July 9, 2025, through pre-established Rule 10b5-1 trading plans.

Summary

• Sanjay Gajendra, President and COO, and Director of Astera Labs, Inc. (ALAB), reported transactions involving the company's common stock.
• On July 9, 2025, a total of 165,000 shares of common stock were sold.
• The sales included 86,685 shares at a weighted average price of $98.5214 (ranging from $98.1000 to $99.0900).
• An additional 38,315 shares were sold at a weighted average price of $99.2093 (ranging from $99.1000 to $99.4200).
• Two separate transactions each involved 20,000 shares, one at a weighted average price of $98.2078 and the other at $98.218 (both ranging from $98.1000 to $98.3400).
• All reported sales were executed automatically pursuant to a Rule 10b5-1 trading plan adopted by Sanjay Gajendra on November 30, 2024.
• Shares were sold directly and indirectly through estate planning trusts (Trust 1, Trust 2, and Trust 3).
• Following these transactions, Sanjay Gajendra directly owns 2,262,318 shares of common stock.
• Indirect beneficial ownership after the transactions includes 5,805,545 shares via Trust 1, 695,000 shares via Trust 2, and 695,000 shares via Trust 3.

Sentiment

Score: 5

Explanation: The transaction is a pre-planned sale under a Rule 10b5-1 plan, which is generally considered a neutral event as it reflects a scheduled divestment rather than a reaction to new company information. While it represents a reduction in insider holdings, the pre-scheduled nature mitigates negative sentiment.

Positives

• Sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than a reactive sale based on new, non-public information.

Negatives

• A significant number of shares were sold by a key executive, which could be interpreted by some investors as a reduction in insider conviction, despite the pre-planned nature of the sales.

Risks

• Potential for market misinterpretation of executive share sales, even when conducted under a Rule 10b5-1 plan, leading to short-term negative sentiment.

Future Outlook

NA

Management Comments

• The sales reported occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2024.
• The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Industry Context

NA

Related Party Transactions

• Sales of common stock were made by estate planning trusts (Trust 1, Trust 2, Trust 3) for which the reporting person is a trustee or has an indirect interest, with the reporting person disclaiming beneficial ownership except for pecuniary interest.

Stakeholder Impact

• Shareholders: May observe a reduction in insider ownership, though the pre-planned nature of the sales under a Rule 10b5-1 plan typically mitigates concerns about insider sentiment.

Key Dates

Recommendation

Keywords

Astera Labs, ALAB, Form 4, Insider Trading, Share Sale, Executive Compensation, Rule 10b5-1, Sanjay Gajendra, Common Stock